Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2017 1
2018 3
2019 5
2020 3
2021 3
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J. Collins DM, et al. Clin Cancer Res. 2021 Feb 1;27(3):807-818. doi: 10.1158/1078-0432.CCR-20-2007. Epub 2020 Oct 29. Clin Cancer Res. 2021. PMID: 33122343 Free PMC article. Clinical Trial.
Acquired Resistance to Antibody-Drug Conjugates.
Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Collins DM, et al. Cancers (Basel). 2019 Mar 20;11(3):394. doi: 10.3390/cancers11030394. Cancers (Basel). 2019. PMID: 30897808 Free PMC article. Review.
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Gaynor N, Blanco A, Madden SF, Moran B, Fletcher JM, Kaukonen D, Ramírez JS, Eustace AJ, McDermott MSJ, Canonici A, Toomey S, Teiserskiene A, Hennessy BT, O'Donovan N, Crown J, Collins DM. Gaynor N, et al. Among authors: collins dm. Br J Cancer. 2023 Oct;129(6):1022-1031. doi: 10.1038/s41416-023-02375-y. Epub 2023 Jul 28. Br J Cancer. 2023. PMID: 37507543 Free PMC article. Clinical Trial.
Innovative Technologies Changing Cancer Treatment.
Charmsaz S, Prencipe M, Kiely M, Pidgeon GP, Collins DM. Charmsaz S, et al. Among authors: collins dm. Cancers (Basel). 2018 Jun 19;10(6):208. doi: 10.3390/cancers10060208. Cancers (Basel). 2018. PMID: 29921753 Free PMC article.
Research Strategies for Low-Survival Cancers.
Conway C, Collins DM, McCann A, Dean K. Conway C, et al. Among authors: collins dm. Cancers (Basel). 2021 Jan 30;13(3):528. doi: 10.3390/cancers13030528. Cancers (Basel). 2021. PMID: 33573275 Free PMC article.
Modulation of P-gp expression by lapatinib.
Dunne G, Breen L, Collins DM, Roche S, Clynes M, O'Connor R. Dunne G, et al. Among authors: collins dm. Invest New Drugs. 2011 Dec;29(6):1284-93. doi: 10.1007/s10637-010-9482-7. Epub 2010 Jul 6. Invest New Drugs. 2011. PMID: 20607587
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.
Roche S, Gaule P, Winrow D, Mukherjee N, O'Neill F, Conlon NT, Meiller J, Collins DM, Canonici A, Fawsi MI, Estepa-Fernández A, Madden SF, Crown J, O'Donovan N, Eustace AJ. Roche S, et al. Among authors: collins dm. PLoS One. 2023 Mar 15;18(3):e0282512. doi: 10.1371/journal.pone.0282512. eCollection 2023. PLoS One. 2023. PMID: 36920947 Free PMC article.
17 results